Retatrutide Cost in New York (2026): Pricing, Insurance, and Compounded Options

What Retatrutide Costs Without Insurance in New York

New Yorkers filling a retatrutide prescription without insurance coverage should expect a retail cash price in the range of $1,000 to $1,200 per month, based on Eli Lilly's pricing strategy across its incretin portfolio. This estimate tracks with Zepbound (tirzepatide), which launched at a list price of $1,059.87 per month for the obesity indication [1].

Retatrutide is the first triple-hormone receptor agonist to reach the market, targeting GIP, GLP-1, and glucagon receptors simultaneously. That triple mechanism produced the highest weight loss of any injectable anti-obesity medication tested in a randomized trial to date. In the phase 2 trial published in the New England Journal of Medicine (N=338), the 12 mg dose produced 24.2% mean body weight reduction at 48 weeks, compared to 2.1% for placebo [2]. That efficacy profile positions retatrutide above both semaglutide 2.4 mg (14.9% in STEP-1, N=1,961) [3] and tirzepatide 15 mg (22.5% in SURMOUNT-1, N=2,539) [4].

New York retail pharmacy pricing varies by borough and chain. Specialty pharmacies in Manhattan may price higher than large-chain pharmacies in outer boroughs or upstate locations. Pharmacy benefit managers (PBMs) negotiate different rates depending on the plan, so even cash-pay customers should call multiple pharmacies. GoodRx-style discount cards do not typically apply to brand-name injectables still under patent.

A retail pharmacist filling a first prescription will need the prescriber's prior authorization paperwork completed before dispensing, even for cash-pay patients. The drug ships as pre-filled pens requiring refrigeration.

New York Medicaid Coverage for Retatrutide

New York Medicaid covers retatrutide for chronic weight management with prior authorization. This makes New York one of the more accessible states for Medicaid enrollees seeking newer anti-obesity medications, since many state Medicaid programs still exclude weight loss drugs entirely.

The prior authorization criteria typically require documentation of a BMI of 30 kg/m² or greater, or BMI of 27 kg/m² or greater with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea). Prescribers must also document a trial of lifestyle modification. The American Association of Clinical Endocrinology (AACE) consensus statement on obesity management recommends pharmacotherapy as an adjunct to behavioral intervention when BMI thresholds are met, stating that "weight-centric treatment should be individualized, targeting the root causes and complications of adiposity" [5].

New York's Medicaid managed care organizations (MCOs), including Healthfirst, Fidelis Care, and Amerigroup, each process PAs through their own formulary committees. Approval timelines range from 24 to 72 hours for standard requests. Denials can be appealed through the MCO's grievance process or through a fair hearing with the New York State Office of Temporary and Disability Assistance.

Medicaid recipients in New York pay no copay for preferred formulary drugs. If retatrutide sits on a non-preferred tier, copays may apply but are capped under New York law [6].

Which New York Insurance Plans Cover Retatrutide

Commercial insurance coverage for retatrutide in New York has expanded through 2026, mirroring a broader national shift toward recognizing obesity as a chronic disease requiring pharmacological treatment. The Endocrine Society's clinical practice guideline on pharmacological management of obesity recommends anti-obesity medications for patients with BMI of 30 or greater, or 27 or greater with comorbidities [7].

Large employer-sponsored plans through UnitedHealthcare, Aetna, and Cigna have added retatrutide to formularies in New York, generally on specialty tiers with prior authorization. Copays on specialty tiers range from $50 to $150 per month after deductible, depending on plan design. Empire BlueCross BlueShield, the dominant carrier in the New York individual market, covers retatrutide on its 2026 formulary with step therapy requirements. Step therapy often requires a documented trial of at least one lower-cost GLP-1 receptor agonist before approval.

New York State mandates that fully insured plans operating under state regulation comply with the state's essential health benefits benchmark. Self-funded employer plans (governed by ERISA) are not bound by state mandates, so coverage varies. Patients on self-funded plans should check directly with their benefits administrator.

Oscar Health and other New York-based insurers on the state marketplace have started covering anti-obesity medications for 2026 plan years, though formulary placement and cost-sharing differ. The Treat and Reduce Obesity Act, if fully implemented at the federal level, would expand Medicare Part D coverage for anti-obesity medications, but as of mid-2026 this legislation remains under congressional review [8].

Is Compounded Retatrutide Legal in New York?

Yes. Compounded retatrutide is available through licensed 503A compounding pharmacies operating under New York State Board of Pharmacy oversight. These pharmacies prepare patient-specific prescriptions using bulk retatrutide active pharmaceutical ingredient (API) sourced from FDA-registered facilities.

The FDA's regulatory framework distinguishes between 503A pharmacies (patient-specific prescriptions with a valid prescriber-patient relationship) and 503B outsourcing facilities (which can produce larger batches without individual prescriptions) [9]. New York permits both models, but 503A pharmacies handle the majority of compounded retatrutide prescriptions in the state.

Compounded retatrutide in New York typically costs between $300 and $500 per month, depending on the dose and pharmacy. That represents a 50% to 70% reduction compared to brand pricing. The compounded product is dispensed as a multi-dose vial requiring reconstitution or as a pre-mixed injectable, depending on the pharmacy.

New York patients choosing between brand and compounded retatrutide should weigh three factors: cost (compounded is significantly cheaper), convenience (brand pens require no mixing), and supply reliability (brand supply depends on Lilly's manufacturing capacity, while compounded supply depends on API availability). Patients with insurance covering the brand product at a manageable copay generally benefit from the standardized dosing and quality assurance of the manufactured product. Patients paying out of pocket often find compounded versions the only financially viable option.

The New York State Board of Pharmacy conducts inspections of 503A facilities and requires compliance with USP 797 sterile compounding standards. Patients should verify that their compounding pharmacy holds a current New York State license and sources API from an FDA-registered supplier.

How Eli Lilly's Savings Card Works in New York

Eli Lilly offers a manufacturer savings card for retatrutide that can reduce out-of-pocket costs for commercially insured patients. The card is accepted at all major New York retail and specialty pharmacies.

Eligibility requires commercial insurance (not Medicare, Medicaid, or other government programs). Patients with commercial coverage may pay as little as $25 per month for a 1-month or 3-month supply, with Lilly covering the remainder up to a specified annual cap. The savings card does not apply to insurance deductibles at all pharmacies, so patients should confirm activation at the point of sale.

New York patients without insurance do not qualify for the standard savings card but may access Lilly's direct patient assistance program if household income falls below 400% of the federal poverty level. For a single-person household in 2026, that threshold is approximately $62,400 per year [10].

To activate the card, patients register online through Lilly's patient portal or receive a card through their prescriber's office. The card links to the patient's pharmacy benefit and applies automatically at checkout. Savings cards cannot be combined with other manufacturer coupons. New York's ban on copay accumulator adjustor programs (effective under state insurance law) means that savings card payments count toward the patient's deductible and out-of-pocket maximum on most fully insured state-regulated plans.

Getting Retatrutide via Telehealth in New York

New York State permits telehealth prescribing of retatrutide. The prescriber must hold a valid New York medical license, and the patient must be physically located in New York at the time of the visit. Audio-video visits satisfy the standard of care requirement for controlled substance and specialty medication prescribing.

Telehealth platforms operating in New York connect patients with licensed clinicians who can evaluate BMI, review comorbidities, order baseline labs (fasting glucose, HbA1c, lipid panel, hepatic function), and prescribe retatrutide with appropriate titration schedules. The standard retatrutide titration begins at a low dose and increases monthly over 16 to 24 weeks to the target maintenance dose.

New York's telehealth parity law requires that commercial insurers cover telehealth visits at the same rate as in-person visits, including for obesity management [11]. Medicaid managed care plans in New York also cover telehealth obesity consultations.

For patients without a local endocrinologist or obesity medicine specialist, telehealth expands access significantly. Rural upstate New York counties have fewer than one endocrinologist per 50,000 residents in many areas. Telehealth platforms that partner with New York-licensed pharmacies can coordinate prescription fulfillment and ship directly to the patient's home.

How Retatrutide Compares to Other Anti-Obesity Medications on Cost

Retatrutide enters a competitive New York market alongside several established anti-obesity injectables. Pricing context matters for patients deciding between options.

Semaglutide 2.4 mg (Wegovy) carries a list price of $1,349.02 per month [3]. Tirzepatide (Zepbound) lists at $1,059.87 per month [1]. Retatrutide's estimated list price falls in a similar range. The key differentiator is efficacy. Dr. Ania Jastreboff, lead investigator of the retatrutide phase 2 trial and associate professor at Yale School of Medicine, noted that "the magnitude of weight reduction observed with retatrutide exceeded that seen with currently available anti-obesity medications" [2].

The glucagon receptor component of retatrutide distinguishes it pharmacologically. Glucagon receptor activation increases energy expenditure and hepatic lipid oxidation, potentially offering benefits for patients with metabolic-associated steatotic liver disease (MASLD). A secondary analysis of the phase 2 data showed significant reductions in liver fat, with some participants achieving complete resolution of hepatic steatosis [12].

Cost per percent body weight lost offers one way to compare value across agents. At the 12 mg dose, retatrutide achieved 24.2% weight loss at 48 weeks. If priced at $1,100 per month, that works out to roughly $545 per percentage point of weight loss over the treatment period. Semaglutide 2.4 mg at $1,349 per month with 14.9% weight loss over 68 weeks costs approximately $1,377 per percentage point. Tirzepatide 15 mg at $1,060 per month with 22.5% weight loss over 72 weeks costs approximately $566 per percentage point [2][3][4].

These calculations are rough and do not account for individual response variability, titration periods, or long-term maintenance dosing. But they illustrate that retatrutide's higher absolute efficacy may translate to better cost-efficiency for many patients.

Safety Considerations That Affect Long-Term Cost

Treatment discontinuation drives hidden costs. Patients who stop retatrutide due to side effects waste the investment in titration and lose achieved weight. The phase 2 trial reported that 6.4% of participants on retatrutide 12 mg discontinued due to adverse events, compared to 2.6% on placebo [2].

The most common adverse events were gastrointestinal: nausea (25.6%), diarrhea (22.1%), and vomiting (9.3%) at the 12 mg dose. These events clustered during the dose-escalation phase and diminished with continued treatment. Slower titration schedules reduce GI side effects, a strategy now standard across incretin-based therapies [13].

The AACE 2023 consensus statement recommends that clinicians "monitor patients on anti-obesity pharmacotherapy at regular intervals, assessing both efficacy and tolerability, with dose adjustments as clinically indicated" [5]. For New York patients managing costs carefully, choosing a prescriber who titrates conservatively can prevent early discontinuation and the associated financial loss.

Baseline labs before starting retatrutide (comprehensive metabolic panel, lipase, thyroid function) are covered by most New York insurance plans as preventive or diagnostic testing. Follow-up labs at 3 and 6 months add modest cost but help identify the rare patient who develops pancreatitis or thyroid abnormalities early enough to intervene.

Retatrutide carries a boxed warning regarding thyroid C-cell tumors based on rodent studies, consistent with all GLP-1 receptor agonist class labeling. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [14].

What New York Patients Should Do Next

Patients interested in retatrutide should start with a clinical evaluation (in person or via telehealth) that includes BMI measurement, comorbidity screening, and baseline metabolic labs. Request that your prescriber submit prior authorization to your insurer concurrently with the first prescription to avoid dispensing delays. If your commercial plan denies coverage, activate the Eli Lilly savings card before appealing. If you are uninsured or underinsured, ask your prescriber about licensed 503A compounding pharmacies in New York that carry retatrutide. The target maintenance dose in the phase 2 trial that produced 24.2% weight loss was 12 mg once weekly by subcutaneous injection [2].